• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
CSL Limited - Product Pipeline Review - Q4 2010 Product Image

CSL Limited - Product Pipeline Review - Q4 2010

  • ID: 1463886
  • December 2010
  • 96 pages
  • Global Markets Direct

CSL Limited – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “CSL Limited - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- CSL Limited - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of CSL Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
CSL Limited Snapshot
CSL Limited Overview
Key Information
Key Facts
CSL Limited – Research and Development Overview
Key Therapeutic Areas
CSL Limited – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
CSL Limited – Pipeline Products Glance
CSL Limited – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
CSL Limited Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
CSL Limited–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
CSL Limited – Drug Profiles
H5N1 Pandemic Flu
Product Description
Mechanism of Action
R&D Progress
Biostate
Product Description
Mechanism of Action
R&D Progress
CSL718
Product Description
Mechanism of Action
R&D Progress
FXIII Concentrate Human
Product Description
Mechanism of Action
R&D Progress
Haemocomplettan
Product Description
Mechanism of Action
R&D Progress
IgG with Proline (IgPro)
Product Description
Mechanism of Action
R&D Progress
Prothrombin complex concentrate
Product Description
Mechanism of Action
R&D Progress
CSL412
Product Description
Mechanism of Action
R&D Progress
H.pylori Vaccine for Gastrointestinal Disoders (CSL Limited)
Product Description
Mechanism of Action
R&D Progress
NY-ESO-1 ISCOMATRIX vaccine
Product Description
Mechanism of Action
R&D Progress
CSL112 rHDL
Product Description
Mechanism of Action
R&D Progress
CSL360
Product Description
Mechanism of Action
R&D Progress
Epstein-Barr Virus Vaccine
Product Description
Mechanism of Action
R&D Progress
Recombumin(R) 20 percent
Product Description
Mechanism of Action
R&D Progress
Albufuse Technology
Product Description
Mechanism of Action
R&D Progress
CSL654
Product Description
Mechanism of Action
R&D Progress
CSL689
Product Description
Mechanism of Action
R&D Progress
Recombinant Coagulation Factors
Product Description
Mechanism of Action
R&D Progress
G-CSF
Product Description
Mechanism of Action
R&D Progress
OpsoVac Technology Platform
Product Description
Mechanism of Action
R&D Progress
Periodontal disease Immunotherapy
Product Description
Mechanism of Action
R&D Progress
POTELLIGENT(R) Technology
Product Description
Mechanism of Action
R&D Progress
XmAb Technology Platform
Product Description
Mechanism of Action
R&D Progress
CSL Limited – Pipeline Analysis
CSL Limited – Pipeline Products by Therapeutic Class
CSL Limited Pipeline Products By Target
CSL Limited – Pipeline Products by Route of Administration
CSL Limited – Pipeline Products by Molecule Type
CSL Limited – Company Statement
CSL Limited – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Oct 07, 2010: CSL Behring Reports Privigen Demonstrates Efficacy Among Patients With Various Immunodeficiencies
Oct 07, 2010: CSL Behring Reports Vivaglobin Study Results For Treatment Of Primary Immunodeficiency
Apr 19, 2010: CSL Behring Receives FDA Approval to Extend Shelf Life for Privigen from 24 to 36 Months
Apr 19, 2010: CSL Behring Receives FDA Approval to Extend Shelf Life for Privigen from 24 to 36 Months
Apr 19, 2010: CSL Behring Receives FDA Approval to Extend Shelf Life for Privigen from 24 to 36 Months
Apr 19, 2010: CSL Behring Receives FDA Approval to Extend Shelf Life for Privigen from 24 to 36 Months
Feb 04, 2010: CSL Behring Announces That Global SWIFT Studies Will Evaluate Safety And Efficacy Of Biostate For Von Willebrand Disease And Hemophilia A
Feb 04, 2010: CSL Behring Announces That Global SWIFT Studies Will Evaluate Safety And Efficacy Of Biostate For Von Willebrand Disease And Hemophilia A
Dec 22, 2009: CSL Announces Publication Of Data From Clinical Trial Of Pandemic H1N1 2009 Vaccine In Journal Of American Medical Association
Nov 12, 2009: FDA approves CSL Biotherapies' Seasonal flu vaccine, Afluria For children
Financial Deals Landscape
CSL Limited, Deals Volume Summary, 2004 to YTD 2010
CSL Limited, Deals Summary By Region, 2004 to YTD 2010
CSL Limited, Deals Summary, 2004 to YTD 2010
CSL Limited Detailed Deal Summary
Acquisition
CSL Acquires Zenyth Therapeutics
Sigma-Aldrich Acquires JRH Biosciences From CSL
CSL Acquires Aventis Behring From Aventis
CSL Terminates The Acquisition Of Talecris Biotherapeutics
Equity Offering
CSL Completes Private Placement Of $1.52 Billion
CSL Enters Into Co-Development Agreement With Sanofi Pasteur
The Walter and Eliza Enters Into Research Agreement With CSL
Opsona Therapeutics Enters Into Co-Development Agreement With CSL
Celltrion Enters Into Co-Development Agreement With CSL
CSL Enters Into Collaboration With EvoGenix
Chiron Enters Into Collaboration Agreement With CSL
Licensing Agreements
Patrys Enters Into Research Agreement With CSL
Xencor Enters Into Licensing Agreement With CSL
DSM Biologics And Crucell Enters Into Licensing Agreement With CSL
BioWa Enters Into Licensing Agreement With CSL
MedImmune Enters Into Licensing Agreement With CSL
CSL Enters Into License Agreement With Wyeth
CSL Enters Into License Agreement With Intendis
Intercell Enters Into Licensing Agreement With CSL
CSL Enters Into License And Option Agreement With Merck
CSL Enters Into Licensing Agreement With Bayer Healthcare
CSL And Merck Enters Into Cross-License Agreement With GlaxoSmithKline
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS